Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
Jia Zhong, Lei Li, Zhijie Wang, Hua Bai, Fei Gai, Jianchun Duan, Jun Zhao, Minglei Zhuo, Yuyan Wang, Shuhang Wang, Wanchun Zang, Meina Wu, Tongtong An, Guanhua Rao, Guanshan Zhu, Jie Wang
Journal of Thoracic Oncology, 2017
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer 2006
- Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status 2009
- Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours 2008
- Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model 2013
- EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib 2007
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data 2010
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors 2011
- Down syndrome cell adhesion molecule DSCAM mediates homophilic intercellular adhesion 2000
- Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival 2015
- BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis 2015